BELLUS Health competitors

Anish Bhatnagar is a Chief Executive Officer at SOLENO THERAPEUTICS INC and Board Member at SOLENO THERAPEUTICS INC and is based in San Francisco Bay Area. He has worked as Senior Vice President, Clinical and Regulatory Affairs at SOLENO THERAPEUTICS INC; President and Chief Operating Officer at SOLENO THERAPEUTICS INC; and Chief Medical Officer at SOLENO THERAPEUTICS INC. Anish studied at SMS Medical College - India, University of Pennsylvania, and Georgetown University.

Neuroscience researcher (over 25 years' experience), Co-Founder and CEO of a bioscience company, Neurolixis, developing clinical-stage drugs for treatment of Parkinson's disease and Rett syndrome. Previously Director of Neurobiology at Pierre Fabre, identifying novel antipsychotic, antidepressant and analgesic drug candidates. Prior to Pierre Fabre, investigated signal transduction of monoamine receptors at the Servier Research Institute. Published over 180 articles in peer-reviewed journals and co-inventor on a dozen patents. Serves as European Councillor for the International Society for Serotonin Research. Principal current focus is the development of the first-in-class serotonergic 'biased agonists' befiradol (NLX-112) and NLX-101 (F15599). Previously characterized several approved drugs, including milnacipran (Savella ®), piribedil (Trivastal ®), agomelatine (Valdoxan ®) and levomilnacipran (Fetzima ®).Specialties: neuropharmacology, drug discovery, target validation, early drug development. Particular interest in "biased agonism" (a.k.a. "functional selectivity").